Safety and effectivity of dupilumab in transplant recipients with severe atopic dermatitis: A multicenter case series

Clicks: 5
ID: 329541
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #213 of 216 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 216 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
This multicenter retrospective case series evaluated the safety and effectiveness of dupilumab in nine solid organ transplant recipients with severe atopic dermatitis. Treatment resulted in rapid and sustained clinical improvement in most patients, with significant reductions in disease severity, pruritus, and quality-of-life impairment, and minimal adverse events. Importantly, no graft dysfunction or need for immunosuppressive adjustment was observed, supporting dupilumab as a promising therapeutic option in this high-risk population.
Reference Key
openalex_W7214118784 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Raquel María Dominguez-Lopez, Mónica Munera-Campos, F.J. Navarro‐Triviño, Trinidad Montero‐Vílchez, Constanza Riquelme‐Mc Loughlin, Rubén Barros‐Tornay, Álvaro González‐Cantero, Emilio Berná-Rico, Enrique Gómez de la Fuente
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag424
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.